The estimated Net Worth of Justin J. File is at least 1.32 百万$ dollars as of 20 December 2021. Mr. File owns over 40,594 units of Evofem Biosciences Inc stock worth over 4,329$ and over the last 7 years he sold EVFM stock worth over 131,768$. In addition, he makes 1,183,010$ as Chief Financial Officer at Evofem Biosciences Inc.
Justin has made over 8 trades of the Evofem Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 40,594 units of EVFM stock worth 15,020$ on 20 December 2021.
The largest trade he's ever made was buying 40,594 units of Evofem Biosciences Inc stock on 20 December 2021 worth over 15,020$. On average, Justin trades about 3,898 units every 29 days since 2018. As of 20 December 2021 he still owns at least 480,982 units of Evofem Biosciences Inc stock.
You can see the complete history of Mr. File stock trades at the bottom of the page.
Justin J. File serves as Chief Financial Officer of the Company. Mr. File has also served as the Chief Financial Officer of the women’s health nonprofit organization WCG Cares from November 2017 to May 2018. Mr. File has approximately 26 years of diverse accounting and finance experience within a variety of both public and private biotechnology and biopharmaceutical companies. Most recently, Mr. File provided executive financial and accounting oversight services to various biotechnology companies in San Diego, California, assisting in their initial public offering process and helping to establish and improve their accounting and finance operations as publicly-traded entities. Prior to this, Mr. File was Senior Director and Controller of Sequenom, Inc., a diagnostic company that developed and commercialized molecular diagnostics testing services for the women’s health market. During that time, Mr. File served as Treasurer of their diagnostic subsidiary and provided assistance in the raising of over $400 million in combined equity and convertible note offerings. Mr. File also assisted in the commercialization of four diagnostic tests in a two-year period, which included Sequenom’s revolutionary noninvasive prenatal test for Down syndrome. Earlier in his career Mr. File worked for approximately ten years in public accounting, primarily with Arthur Andersen LLP, where he worked with a variety of clients assisting with attestation and periodic reporting requirements, public offerings and acquisitions. Mr. File graduated from Central Washington University with a Bachelor of Science in Accounting and Business Administration and is a Certified Public Accountant (inactive).
As the Chief Financial Officer of Evofem Biosciences Inc, the total compensation of Justin File at Evofem Biosciences Inc is 1,183,010$. There are 5 executives at Evofem Biosciences Inc getting paid more, with Saundra Pelletier having the highest compensation of 2,803,980$.
Justin File is 49, he's been the Chief Financial Officer of Evofem Biosciences Inc since 2018. There are 12 older and 2 younger executives at Evofem Biosciences Inc. The oldest executive at Evofem Biosciences Inc is Gillian Greer, 75, who is the Independent Director.
Justin's mailing address filed with the SEC is C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO, CA, 92130.
Over the last 7 years, insiders at Evofem Biosciences Inc have traded over 32,368,585$ worth of Evofem Biosciences Inc stock and bought 12,978,479 units worth 54,857,186$ . The most active insiders traders include Research Corp Acacia、Fund Solutions Ltd Link、Biopharma, Inc. Pdl. On average, Evofem Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of 5,281$. The most recent stock trade was executed by Yan Zhang on 12 January 2024, trading 104 units of EVFM stock currently worth 4$.
evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.
Evofem Biosciences Inc executives and other stock owners filed with the SEC include: